In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma

David J. Verbik; Warren W. Stinson; Michael J. Brunda; Anne Kessinger; Shantaram S. Joshi

In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma

David J. Verbik, Warren W. Stinson, Michael J. Brunda, Anne Kessinger, Shantaram S. Joshi

Research output: Contribution to journal › Article › peer-review

Abstract

Despite considerable advancement in anticancer therapy, minimal residual disease (MRD) is still a major problem in the clinical management of cancer, including lymphoma. In this report, we have studied the antitumor effects of interleukin-12 (IL-12) against an aggressive liver metastatic murine RAW117-H10 lymphoma Our results using three different doses of IL-12 (0.175, 0.35 and 0.7 μg/mouse) showed that a 0.35 μg dose is the most efficacious against lymphoma grown in intact mice. Furthermore, we have evaluated the therapeutic effects of IL-12 against residual lymphoma in a transplantation setting. BALB/c mice were treated with high-dose therapy (HDT) and transplanted with syngeneic bone marrow cells added with a known number of RAW117-H10 lymphoma cells to mimic the clinical situation of MRD. The mice were then treated with IL-12 (0.25 μg/mouse/day) alone or IL-12 plus activated cytotoxic effector cells. Our results showed that IL-12 had a significant (P < 0.05) antitumor therapeutic effect against liver metastatic lymphoma grown in intact mice as well as in lymphoma-bearing mice treated with HDT followed by stem cell transplantation as determined by survival period. The therapeutic effect of IL-12 was also demonstrated by a very significant decrease (P < 0.05) in the tumor burden in livers from the IL-12-treated mice. Mice that were treated with IL-12 following HDT and hematopoietic stem cell transplantation had a significant decrease in circulating white blood cells (P < 0.05), a significant increase in spleen weight and cellularity (P < 0.05), and hematopoietic progenitor cells (P < 0.05), a significant increase in the number of splenocytes expressing IL-2 α-chain receptor (P < 0.05), and an increase in the frequency of natural killer cells in their spleens. These studies suggest that cytokines such as IL-12 may have the potential to mediate antitumor effects against residual lymphoma without compromising lymphohematopoietic recovery.

Original language	English (US)
Pages (from-to)	219-229
Number of pages	11
Journal	Clinical and Experimental Metastasis
Volume	14
Issue number	3
State	Published - 1996

Keywords

Antitumor effects
Immune augmentation
Interleukin-12
Residual lymphoma

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{71f0b5666a444d938014c59f34f02692,

title = "In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma",

abstract = "Despite considerable advancement in anticancer therapy, minimal residual disease (MRD) is still a major problem in the clinical management of cancer, including lymphoma. In this report, we have studied the antitumor effects of interleukin-12 (IL-12) against an aggressive liver metastatic murine RAW117-H10 lymphoma Our results using three different doses of IL-12 (0.175, 0.35 and 0.7 μg/mouse) showed that a 0.35 μg dose is the most efficacious against lymphoma grown in intact mice. Furthermore, we have evaluated the therapeutic effects of IL-12 against residual lymphoma in a transplantation setting. BALB/c mice were treated with high-dose therapy (HDT) and transplanted with syngeneic bone marrow cells added with a known number of RAW117-H10 lymphoma cells to mimic the clinical situation of MRD. The mice were then treated with IL-12 (0.25 μg/mouse/day) alone or IL-12 plus activated cytotoxic effector cells. Our results showed that IL-12 had a significant (P < 0.05) antitumor therapeutic effect against liver metastatic lymphoma grown in intact mice as well as in lymphoma-bearing mice treated with HDT followed by stem cell transplantation as determined by survival period. The therapeutic effect of IL-12 was also demonstrated by a very significant decrease (P < 0.05) in the tumor burden in livers from the IL-12-treated mice. Mice that were treated with IL-12 following HDT and hematopoietic stem cell transplantation had a significant decrease in circulating white blood cells (P < 0.05), a significant increase in spleen weight and cellularity (P < 0.05), and hematopoietic progenitor cells (P < 0.05), a significant increase in the number of splenocytes expressing IL-2 α-chain receptor (P < 0.05), and an increase in the frequency of natural killer cells in their spleens. These studies suggest that cytokines such as IL-12 may have the potential to mediate antitumor effects against residual lymphoma without compromising lymphohematopoietic recovery.",

keywords = "Antitumor effects, Immune augmentation, Interleukin-12, Residual lymphoma",

author = "Verbik, {David J.} and Stinson, {Warren W.} and Brunda, {Michael J.} and Anne Kessinger and Joshi, {Shantaram S.}",

year = "1996",

language = "English (US)",

volume = "14",

pages = "219--229",

journal = "Clinical and Experimental Metastasis",

issn = "0262-0898",

publisher = "Springer Science and Business Media B.V.",

number = "3",

}

TY - JOUR

T1 - In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma

AU - Verbik, David J.

AU - Stinson, Warren W.

AU - Brunda, Michael J.

AU - Kessinger, Anne

AU - Joshi, Shantaram S.

PY - 1996

Y1 - 1996

N2 - Despite considerable advancement in anticancer therapy, minimal residual disease (MRD) is still a major problem in the clinical management of cancer, including lymphoma. In this report, we have studied the antitumor effects of interleukin-12 (IL-12) against an aggressive liver metastatic murine RAW117-H10 lymphoma Our results using three different doses of IL-12 (0.175, 0.35 and 0.7 μg/mouse) showed that a 0.35 μg dose is the most efficacious against lymphoma grown in intact mice. Furthermore, we have evaluated the therapeutic effects of IL-12 against residual lymphoma in a transplantation setting. BALB/c mice were treated with high-dose therapy (HDT) and transplanted with syngeneic bone marrow cells added with a known number of RAW117-H10 lymphoma cells to mimic the clinical situation of MRD. The mice were then treated with IL-12 (0.25 μg/mouse/day) alone or IL-12 plus activated cytotoxic effector cells. Our results showed that IL-12 had a significant (P < 0.05) antitumor therapeutic effect against liver metastatic lymphoma grown in intact mice as well as in lymphoma-bearing mice treated with HDT followed by stem cell transplantation as determined by survival period. The therapeutic effect of IL-12 was also demonstrated by a very significant decrease (P < 0.05) in the tumor burden in livers from the IL-12-treated mice. Mice that were treated with IL-12 following HDT and hematopoietic stem cell transplantation had a significant decrease in circulating white blood cells (P < 0.05), a significant increase in spleen weight and cellularity (P < 0.05), and hematopoietic progenitor cells (P < 0.05), a significant increase in the number of splenocytes expressing IL-2 α-chain receptor (P < 0.05), and an increase in the frequency of natural killer cells in their spleens. These studies suggest that cytokines such as IL-12 may have the potential to mediate antitumor effects against residual lymphoma without compromising lymphohematopoietic recovery.

AB - Despite considerable advancement in anticancer therapy, minimal residual disease (MRD) is still a major problem in the clinical management of cancer, including lymphoma. In this report, we have studied the antitumor effects of interleukin-12 (IL-12) against an aggressive liver metastatic murine RAW117-H10 lymphoma Our results using three different doses of IL-12 (0.175, 0.35 and 0.7 μg/mouse) showed that a 0.35 μg dose is the most efficacious against lymphoma grown in intact mice. Furthermore, we have evaluated the therapeutic effects of IL-12 against residual lymphoma in a transplantation setting. BALB/c mice were treated with high-dose therapy (HDT) and transplanted with syngeneic bone marrow cells added with a known number of RAW117-H10 lymphoma cells to mimic the clinical situation of MRD. The mice were then treated with IL-12 (0.25 μg/mouse/day) alone or IL-12 plus activated cytotoxic effector cells. Our results showed that IL-12 had a significant (P < 0.05) antitumor therapeutic effect against liver metastatic lymphoma grown in intact mice as well as in lymphoma-bearing mice treated with HDT followed by stem cell transplantation as determined by survival period. The therapeutic effect of IL-12 was also demonstrated by a very significant decrease (P < 0.05) in the tumor burden in livers from the IL-12-treated mice. Mice that were treated with IL-12 following HDT and hematopoietic stem cell transplantation had a significant decrease in circulating white blood cells (P < 0.05), a significant increase in spleen weight and cellularity (P < 0.05), and hematopoietic progenitor cells (P < 0.05), a significant increase in the number of splenocytes expressing IL-2 α-chain receptor (P < 0.05), and an increase in the frequency of natural killer cells in their spleens. These studies suggest that cytokines such as IL-12 may have the potential to mediate antitumor effects against residual lymphoma without compromising lymphohematopoietic recovery.

KW - Antitumor effects

KW - Immune augmentation

KW - Interleukin-12

KW - Residual lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0030059125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030059125&partnerID=8YFLogxK

M3 - Article

C2 - 8674276

AN - SCOPUS:0030059125

SN - 0262-0898

VL - 14

SP - 219

EP - 229

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

IS - 3

ER -

In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this